Hepatic Artery Infusion of Adebrelimab Combined With Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma With Failure of Systemic Therapy Combined With Interventional Therapy

Sponsor
HuiKai Li
Study ID
NCT05975463
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • HAIC — PROCEDURE
    hepatic artery infusion for 3-4 times.
  • Adebrelimab — DRUG
    hepatic artery infusion of Adebrelimab 1200mg, d1, q3w，for 3-4 times.
  • Bevacizumab — DRUG
    hepatic artery infusion of Bevacizumab 5mg/kg, d1, q3w, for 3-4 times.

Study Details

The goal of this prospective single arm, Phase II Clinical Study is to explore and evaluate the efficacy and safety of hepatic artery infusion of Adebrelimab combined with Bevacizumab in the treatment of patients with advanced hepatocellular carcinoma who failed in systematic therapy combined with interventional therapy. Participants will receive hepatic artery infusion of Adebrelimab 1200mg, d1, q3w, combined with hepatic artery infusion of Bevacizumab 5mg/kg, d1, q3w, HAIC treatment for 3-4 times.

Key Dates

First listed
Aug 4, 2023
Start date
Sep 15, 2023
Status verified
Aug 2023
Primary completion
Jul 31, 2025
Completion
Jul 31, 2026

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: HAIC+Adebrelimab+Bevacizumab
    hepatic artery infusion of Adebrelimab 1200mg, d1, q3w, combined with hepatic artery infusion of Bevacizumab 5mg/kg, d1, q3w, HAIC treatment for 3-4 times.

Primary Outcome Measure

Objective response rate (ORR) [ Time Frame: Up to one year ]

Related Studies